ACADIA Pharmaceuticals Inc (NASDAQ:ACAD)
| 31.08 Delayed Data As of Aug 18 |  +0.05 / +0.16%Today’s Change | 20.68 Today|||52-Week Range 40.83 | +7.77% Year-to-Date |
Latest ACAD News | Press Releases
| Jazz Pharmaceuticals Arm Announces $500M Senior Notes Offer Aug 18 / Zacks.com - Paid Partner Content | What You See, and What You Get: The Neurology of Perception Aug 15 / Zacks.com - Paid Partner Content |
| FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa Aug 17 / Zacks.com - Paid Partner Content | Geron's (GERN) Imetelstat Progressing Well, Setbacks Concern Aug 14 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 31.03 |
| Today’s open | 31.04 |
| Day’s range | 30.87 - 31.40 |
| Volume | 909,596 |
| Average volume (3 months) | 1,535,890 |
| Market cap | $3.8B |
| Dividend yield | -- |
Data as of 4:00pm ET, 08/18/2017
Growth & Valuation
| Earnings growth (last year) | -43.56% |
| Earnings growth (this year) | -9.83% |
| Earnings growth (next 5 years) | +28.93% |
| Revenue growth (last year) | +28,311.48% |
| P/E ratio | NM |
| Price/Sales | 192.80 |
| Price/Book | 7.28 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| AKRXAkorn Inc | -0.62 | -1.90% |
| AGNPRAAllergan plc | -1.14 | -0.14% |
| MNKMallinckrodt Plc | +0.03 | +0.08% |
| CLVSClovis Oncology Inc | +2.09 | +2.99% |
Data as of 4:01pm ET, 08/18/2017
Financials
| Next reporting date | November 6, 2017 |
| EPS forecast (this quarter) | -$0.64 |
| Annual revenue (last year) | $17.3M |
| Annual profit (last year) | -$271.4M |
| Net profit margin | -1,565.94% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Stephen R. Davis |
Vice President-Technology Development & Operations James A. Nash |
Corporate headquarters San Diego, California |
Forecasts
